Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.50 |
| ▸ | NPC1 | O15118 | 6/20 | 0.50 |
| ▸ | RAB9A | P51151 | 6/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 3/20 | 0.49 |
| ▸ | MITF | O75030 | 2/20 | 0.48 |
| ▸ | PAX8 | Q06710 | 2/20 | 0.48 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.48 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.48 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.48 |
| ▸ | RELA | Q04206 | 1/20 | 0.48 |
| ▸ | KLF5 | Q13887 | 1/20 | 0.48 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL59705 | 0.85 | NPC1 (0.66) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL28115910 | 0.84 | NPC1 (0.65) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2956601 | 0.81 | ALDH1A1 (0.54) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2950874 | 0.79 | NR1H4 (0.47) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2950872 | 0.79 | NPC1 (0.52) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2947575 | 0.75 | MDH1 (0.60) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL28837191 | 0.74 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL29606712 | 0.74 | ALDH1A1 (0.55) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2954690 | 0.74 | APOBEC3G (0.53) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A | |
| SCHEMBL2959883 | 0.72 | MAPT (0.66) | SMN1; SMN2NPC1RAB9AALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7763656-B2 | Use of Acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2010-07-27 | — | — | US | disclosed |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2007-08-30 | — | — | US | disclosed |
| US-7247741-B2 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. (US) | 2007-07-24 | — | — | US | disclosed |
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | PTC THERAPEUTICS, INC. | 2006-07-27 | — | — | US | disclosed |
| EP-1525185-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC Therapeutics, Inc. (US) | 2005-04-27 | — | — | EP | disclosed |
| WO-2004009533-A1 | ACETYLAMINO BENZOIC ACID COMPOUNDS AND THEIR USE FOR NONSENSE SUPPRESSION AND THE TREATMENT OF DISEASE | PTC THERAPEUTICS, INC. (US) | 2004-01-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060167263-A1 | Acetylamino benzoic acid compounds and their use for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | SMN1; SMN2 23/4885NPC1 1202/4885RAB9A 2946/4885 |
| US-20070203123-A1 | Use of acetylamino benzoic acid compounds for nonsense suppression and the treatment of disease | UPF1, NAT10, PABPC1 | SMN1; SMN2 27/4885NPC1 1463/4885RAB9A 3119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.